Biotech

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients

Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients

Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%

Biotech Recent News

Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards

Psyence Biomed secures Nasdaq extension to meet compliance by December 31, advancing psilocybin-based therapeutics for mental health treatments.

Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate

Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021.

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs

Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement.

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints.

Cannabis Robots And The Search For Good Jobs: A Veteran's Mission To Keep The US Ahead In The Tech Race

At C4, in Chico, California, the benefits of automation go beyond efficiency—they also create opportunities for community development.

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies.

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges

Incyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations.

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential

Alzamend Neuro's AL001 study highlights safety and therapeutic potential for Alzheimer's and psychiatric conditions, reducing systemic side effects.

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases

Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.

Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges.

Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost

Novo Nordisk launches Wegovy in China to address rising obesity rates, priced lower than in the U.S. Initial sales start at a Shanghai public hospital.